Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing medical
technologies for the long-term treatment of chronic debilitating metabolic
diseases including diabetes, blood disorders such as haemophilia and other
diseases, today announced the appointment of Mr. Frank Holler to its Board of
Directors. A Vancouver-based entrepreneur and investor, Holler brings 25 years
of success-driven experience in the biopharma and technology sectors to
Sernova's board. He has been directly involved in the founding and development
of some of Canada's most successful biopharma companies including ID Biomedical,
Angiotech Pharmaceuticals and Xenon Pharmaceuticals. 


"Frank possesses the ideal combination of coveted bio-science experience and
strategic relationships with institutions and pharma to guide Sernova's
strategic advancement," stated Dr. George Adams, Sernova's Board Chair. 


"I am pleased to be joining the board of Sernova," said Mr. Holler. "Sernova's
CEO, Dr. Philip Toleikis is a former Angiotech colleague and I am looking
forward to working with him and the Sernova team as we advance Sernova's
therapeutic cell-based product development programs and drive value for
shareholders." 


Mr. Holler previously served as President & CEO of Xenon Pharmaceuticals, Inc.,
a genetics-based drug development company focused on the treatment of rare
inherited medical conditions, President & CEO of ID Biomedical Corporation, a
vaccine development company sold to GlaxoSmithKline in 2005, and was a founding
director of Angiotech Pharmaceuticals, a TSX/NASDAQ-listed biotechnology
company. He was also an investment banker with Merrill Lynch Canada and Wood
Gundy, Inc. (now CIBC World Markets) and former director of the British Columbia
Biotechnology Association (now LifeSciences BC), and in 2003 received the BC
Biotech Award for Vision and Leadership. 


"Frank's extensive industry experience, capital markets expertise and strategic
insights will be very helpful as Sernova continues to advance its programs,"
said Dr. Philip Toleikis, President and CEO of Sernova. "In particular, I
believe his background in corporate finance, strategic partnering and M&A will
be a good fit for Sernova as we continue to build out the Company's leading
position in regenerative medicine." 


Sernova also announces that it has granted an aggregate of 150,000 incentive
stock options on February 11, 2014 to certain directors of the Company to
purchase common shares in the capital stock of the Company subject to approval
of the TSX Venture Exchange. Each option entitles the holder to purchase one
common share of the Company at an exercise price of $0.15, for a period of 5
years, in accordance with the provisions of the Sernova Stock Option Plan. 


About Sernova 

Sernova Corp is a clinical stage regenerative medicine company developing
medical technologies for the treatment of chronic debilitating metabolic
diseases such as diabetes, blood disorders including haemophilia and other
diseases treated through replacement of proteins or hormones missing or in short
supply within the body. Sernova is developing the Cell Pouch(TM), an implantable
medical device for therapeutic cells (donor, xenogeneic or stem cells) which
then release proteins and/or hormones as required. The therapeutic cells are
protected from immune attack by Sernova's proprietary technology, Sertolin(TM). 


About the Cell Pouch(TM) 

The Cell Pouch(TM) is a proprietary scalable biocompatible medical device,
contract manufactured (ISO13485) to meet international regulatory standards. It
is inserted under the skin, and forms an ideal environment, rich in microvessels
and tissue matrix for the placement and function of therapeutic cells. The Cell
Pouch(TM) is currently being evaluated in clinical trials at the University of
Alberta with Dr. James Shapiro as principal investigator in patients with Type 1
diabetes receiving an islet transplant. 


About Sertolin(TM) 

Sertoli cells when co-localized with donor therapeutic cells release protective
factors that can provide a non-toxic, immune-protected environment that may
reduce or eliminate the need for daily anti-rejection drugs that currently must
be used by patients with transplanted tissues and organs. Sernova is currently
conducting preclinical studies to optimize sertoli cells and islets within the
Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the
Government of Canada. 


About Clinical Islet Transplantation Program 

Please view www.islet.ca for more information on the Clinical Islet
Transplantation Program at the University of Alberta.


Forward-Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward-looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sernova Corp
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
philip.toleikis@sernova.com
info@sernova.com


Sernova Corp
Cathy Steiner, CPA CA MSc MBA
CFO
(416) 566-7870
cathy.steiner@sernova.com
www.sernova.com


Ray Matthews & Associates
Suite 601-128 West Cordova Street,
Vancouver, BC V6B 0E6
(604) 818-7778
www.raymatthews.ca
Sernova (TSXV:SVA)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Sernova Charts.
Sernova (TSXV:SVA)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Sernova Charts.